Saturday, August 10, 2019 2:20:54 PM
provided, however, that to remain on OTCQB a Company must at all times have on file audited
financials dated within the prior 18 months as required to qualify for the Blue Sky securities
secondary trading exemptions described in Section 2.2(5) of these OTCQB Standards.
3) In the event the Company regains compliance with requirements under Section 2 of these
OTCQB Standards subsequent to its Removal Date, OTC Markets Group may, in its sole and
absolute discretion, readmit the Company to the OTCQB market under the following conditions:
a. If the Company regains compliance within 30 calendar days of Removal Date and has not
completed or announced a corporate action during this time, OTC Markets Group may
readmit the Company to the OTCQB market with no further action required;
b. If the Company regains compliance within 30 calendar days of Removal Date and has
completed or announced a corporate action during this time, the Company must submit a
new OTCQB Certification for review and approval by OTC Markets Group;
c. If the Company regains compliance more than 30 calendar days and less than six months
after Removal Date, the Company must submit a new OTCQB Certification for review and
approval by OTC Markets Group; and
d. If the Company regains compliance more than six months after Removal Date, the Company
must submit a new OTCQB Application and Agreement. OTC Markets Group will review the
Application and Agreement pursuant to Section 1.4 of these of these OTCQB Standards. A
new Application Fee is due upon submission of the Application and Agreement.
Note: With respect to items (a) and (b) above, if a Company has not paid its OTCQB Annual
Fee and is removed from OTCQB, but subsequently pays such fee within 30 calendar days of
the Removal Date and otherwise meets the OTCQB eligibility requirements, the Company may,
in OTC Markets Group’s sole and absolute discretion, rejoin OTCQB without submitting a new
Application and Agreement or paying a new Application Fee. If no payment is received within
30 days after the service period end date, the prior OTCQB Application and Agreement is void
and a new Application and Agreement, and Application Fee, will be required.
Recent CELZ News
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 10/23/2024 08:27:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2024 08:23:39 PM
- Creative Medical Technology Holdings Announces $1.85 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 10/23/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/16/2024 04:15:14 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2024 08:45:55 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM